Kornimate/medical-research-clean huggingface dataset:
the role of clinical parameters in predicting the severity of obstructive sleep apnea

Conditions: Obstructive Sleep Apnea; Snoring

Summary: investigate the role of clinical parameters in predicting the severity of obstructive sleep apnea

during the last two decades the obstructive sleep apnea syndrome (osas) has been increasingly recognized as a distinct clinical entity. this condition is caused by recurrent upper airway obstruction during sleep, is manifest as loud snoring, arterial oxygen desaturation, sleep fragmentation, and excessive daytime sleepiness1,2. epidemiological series have shown that about 4% of the population suffers from symptomatic osas that requires treatment3-5. osas is associated with increased rates of many chronic diseases6,7 and is a serious and potentially life-threatening disorder that is far more common than generally believed. thus, untreated osas may pose a significant public health problem8. epidemiological data demonstrating the relationship between osas and cardiovascular morbidity highlight the potential importance of early recognition and treatment9. the mechanisms responsible for upper airway obstruction in patients with osas are highly complicated and as yet not fully understood. several causes for osas have been suggested. it appears to result from a variable combination of anatomic and pathophysiologic factors, some of which may be under genetic control10. the relaxation of upper airway musculature has been studied in relation to osas11-13. anatomic narrowing of the upper airway as a result of alterations in craniofacial morphology or soft tissue enlargement, the bernoulli effect, sleep posture, age, male gender, and adipose tissue in the pharynx have been suggested in the etiology of osas14-17. several studies have suggested that ethnicity may be an important risk factor in osas17-20. recent reports have suggested that asian subjects with osas have a greater severity of illness compared with white subjects21,22. some studies reported that obesity is the strongest risk factor for osas in middle-aged adults3,23,24. however, we have treated many non-obese taiwanese young adults with severe osas. previous researches have suggested that there may be differences in obesity and craniofacial anatomy as risk factors between asians and whites25 and that the etiology of osas in obese patients may be different from that in non-obese patients16,26,27. it is still unclear whether there are differences in clinical evaluation parameters between non-obese asian patients with severe osas and simple snoring. we hypothesized that there are predictor factors in routine clinical examinations for diagnosis of osas in non-obese young adult patients. therefore, the objectives of this study are to compare the clinical parameters in non-obese patients with severe osas with those of simple snorers and to find the risk factors for osas in a non-obese young adult taiwanese population.

Eligibility criteria:
inclusion criteria: * obstructive sleep apnea or snoring patients exclusion criteria: * patients with any concurrent medical illnesses except hypertension

Keywords: obstructive sleep apnea snoring collapsibility upper airway
effect of 10mg domperidone on gastric emptying of a high-fat meal and appetite sensations in healthy adults

Conditions: Diabetes Mellitus

Summary: the purpose of this study is to determine whether domperidone was sufficient to accelerate gastric emptying of a high-fat solid meal and reduce satiety responses in a healthy adult population.

this study aims to investigate the effect of domperidone on gastric emptying and appetite sensations in healthy subjects. domperidone is a dopamine 2 (d2) receptor antagonist with claims of gastrointestinal tract pro-kinetic activity. accelerated gastric emptying (ge) may lead to reduced satiation, increased food intake and is associated with obesity and diabetes mellitus. it is hypothesized that domperidone will increase gastric emptying rate and reduce satiety responses to a high-fat meal. the effect of acute oral administration of 10 mg domperidone on gastric emptying of a high-fat pancake test meal, and subjective appetite sensations by visual analogue scale will be measured for six hours postprandially in a randomized, placebo-controlled, single-blinded manner in 13 healthy subjects.

Eligibility criteria:
inclusion criteria: * healthy adults aged 18-40 years exclusion criteria: * history of gastrointestinal-related conditions, diabetes mellitus or cardiovascular disease

Keywords: domperidone gastric emptying obesity diabetes mellitus domperidone/pharmacology pharmacologic actions physiological effects of drugs gastrointestinal agents humans
transcatheter arterial embolization for elbow and foot plantar pain

Conditions: Elbow Tendinitis; Elbow Tendinopathy; Epicondylitis of the Elbow; Epicondylitis, Lateral; Plantar Fascitis; Embolization

Summary: this is a prospective single arm study in which patients with moderate to severe chronic elbow or foot plantar pain, in the setting of lateral epicondylitis or plantar fascitis refractory to conservative treatment, will be enrolled. the primary aim of this study is to estimate the effectiveness and safety of transcatheter arterial embolization (tae) for changes in elbow or plantar pain with 6 and 12-month follow-up.

this is a prospective single arm, single center study at chung-ang university hospital. patients with moderate to severe elbow or foot pain, and pain refractory to at least 6 months of physician directed conservative therapy (oral analgesic, physical therapy or local injection treatment) will be eligible for enrollment. transcatheter arterial embolization (tae) is performed after receiving informed consent, and imipenem is used as an embolic material to embolize the target lesion. after the procedure, evaluate the vas score and limitation of range of motion (lom) of the joint area. follow-up at 1, 3, 6 and 12 months after embolization, and changes of vas score and lom are checked.

Eligibility criteria:
inclusion criteria: * patients who voluntarily signed a written consent form after receiving an explanation of the purpose, method, and effects of this clinical trial * patients who have had pain in the relevant area for more than 6 months and have a history of receiving physical therapy, analgesic anti-inflammatory medication, or local injection treatment * patients in whom hypervascularization was confirmed in the relevant area through imaging results (us, ct, mri) evaluating the cause of pain. exclusion criteria: * patients are pregnant or breastfeeding * local infection in the painful area * patients have a bleeding disease
muscle evaluation of patients infected by the coronavirus

Conditions: SARS-CoV-2 Acute Respiratory Disease

Summary: patients with severe acute respiratory syndrome coronavirus 2 (sars-cov-2) presents risk to develop muscle weakness associated with prolonged period of mechanical ventilation support and hospital stay.

intensive care unit (icu) acquired muscle weakness affects both respiratory and peripheral muscles and can contribute to worsen clinical and functional outcomes. in this way, ultrasonography muscle evaluation could help to identify early alterations guiding the therapeutic planning and allowing to monitor the interventions performed. therefore, the investigators intend to follow up mechanically ventilated patients with confirmed diagnosis of covid-19 during icu stay to quantify the diaphragm, parasternal intercostal, abdominals and femoral quadriceps muscles thickness assessed by ultrasonography. additionally, functional capacity, frailty and level of physical activity will be evaluated and followed for pre-admission condition and 30, 90 and 180 days after hospital discharge .

Eligibility criteria:
inclusion criteria: * patients admitted to icu * having a confirmed diagnosis of covid-19 * requiring invasive mechanical ventilation. exclusion criteria: * exclusive palliative care; * neuromuscular diseases; * patients who evolve with the need for lower limb amputation; * previous known diaphragm malformations and dysfunctions; * patients transferred from other institutions under invasive mechanical ventilation; * clinical conditions that make the respiratory and peripheral muscle assessment through ultrasound unfeasible.

Keywords: coronavirus sars-cov-2 covid-19 intensive care units ultrasonography
art therapy program in the chronic phase of stroke

Conditions: Stroke

Summary: introduction: after stroke, perceptual impairments, such as negative body perception, contribute to social isolation and depression. in the subacute poststroke phase, art therapy is effective in improving depression, self-esteem, and community integration. yet, no study has explored the effectiveness of art therapy at the chronic stage of a stroke; where motor recovery is slowed, and body image and self-esteem are deeply challenged. objectives: primary; to assess the feasibility of an art therapy program (atp) in the chronic phase of stroke. secondary; to explore the effects of atp on perceptual impairment (body image/self-esteem), mood and community integration. method: nine adults (stroke ≥6 months) will participate in the atp consisting of a thematic group visit to the montreal museum of fine arts followed by an art workshop, supervised by an art therapist (7 visits over 4 months). feasibility will be evaluated by triangulating data from interviews and subject assessment questionnaires and by assessing retention and attendance. the effects of the atp will be assessed by changes in perceptual and mood impairment questionnaires (body image states, self-esteem scales, beck depression inventory-short-form) and community integration questionnaire (the community integration questionnaire). expected results and outcomes: the project will confirm the feasibility of atp to improve perceptual impairment and community integration post-stroke.


Eligibility criteria:
inclusion criteria: * be in the chronic stroke phase (≥ 6 months since diagnosis) * present a low score on the self-esteem scale (score \< 32/40 on the french-canadian self esteem scale) * present mild to moderate degree of depression (score 4 to 15 in the beck depression abbreviated inventory) exclusion criteria: * unable to move autonomously and safely on their own * present aphasia (score \< 28/35 in the communication section of the stroke impact scale) * present severe hemineglect (score \> 70% in the line cancelation test) * present severe spasticity of the hemi-body (score ≥ 3 on the modified ashworth scale) * present cognitive impairment (score ≤ 2/5 in the mini-cog)

Keywords: art therapy perceptual impairment depression
acalabrutinib (acp-196) in combination with acp-319, for treatment of b-cell malignancies

Conditions: Non-Hodgkins Lymphoma; Multiple Myeloma; B-All

Summary: this study is evaluating the safety, pharmacokinetics (pk), pharmacodynamics (pd), and efficacy acalabrutinib and acp 319 in b-cell malignancies.

part 1, dose escalation, is comprised of 3 dosing cohorts of 6 subjects each. acalabrutinib dosing is fixed in all cohorts at 100 mg po twice daily (bid). in addition to acalabrutinib, subjects in cohort 1 will receive acp-319, 25 mg bid; cohort 2 will receive acp-319, 50 mg bid: and cohort 3 will receive acp-319 100 mg bid. the maximum tolerated dose (mtd) of the study treatment combination will be determined by assessing dose-related toxicities (dlts) for each cohort at the end of cycle 1 prior to dose escalation. if there are greater than or equal to 2 dlts in a cohort, dose escalation will not occur and the mtd will be the highest daily dose for which less than 33% of the subjects in that cohort experienced dlts in cycle 1. part 2, dose expansion, includes 12 subjects per histology, dosing at the mtd for the combination of acalabrutinib and acp-319 established in part 1. subjects will continue dosing until disease progression or unacceptable drug-related toxicity.

Eligibility criteria:
main inclusion criteria: * diagnosis of a b-cell malignancy as documented by medical records and with histology based on criteria established by the world health organization (who). * eastern cooperative oncology group (ecog) performance status of ≤ 2. * agreement to use contraception during the study and for 90 days after the last dose of study drugs if sexually active and able to bear or beget children. exclusion criteria * a life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of study drugs, or put the study outcomes at undue risk. * central nervous system (cns) involvement by lymphoma/leukemia * any therapeutic antibody within 4 weeks of first dose of study drugs. * the time from the last dose of the most recent chemotherapy or experimental therapy to the first dose of study drugs is \< 5 times the half-life of the previously administered agent(s). * anc \< 0.5 x 10\^9/l or platelet count \< 50 x 10\^9/l unless due to disease involvement in the bone marrow. * creatinine \> 1.5 x institutional upper limit of normal (uln); total bilirubin \> 1.5 x uln (unless due to gilbert's disease); and aspartate aminotransferase (ast) or alanine aminotransferase (alt) \> 3.0 x uln.

Keywords: bruton tyrosine kinase inhibitor btk b-cell malignancies mantle cell multiple myeloma cll sll dlbcl follicular waldenstrom b-all
open label, multicenter, randomized, controlled study of im or oral exemestane (aromasin) in postmenopausal women

Conditions: Breast Neoplasms

Summary: the purpose of this study is to find out if the two different formulations of exemestane (aromasin), oral and injectable, are equivalent in terms of pharmacodynamics and pharmacokinetics, i.e., if ultimately both formulations have the same efficacy in postmenopausal women with metastatic breast cancer who have failed previous antiestrogens therapy and are equally safe.


Eligibility criteria:
inclusion criteria: * other diagnosed with breast cancer * estrogen receptor positivity * postmenopausal status * advanced disease * progression to previous tamoxifen therapy exclusion criteria: * more than 1 chemotherapy and / or more than 1 hormonotherapy for advanced disease * previous hormonotherapy other than tamoxifen
use of topical phenytoin in bisphosphonate-related osteonecrosis of the mandible

Conditions: Osteonecrosis Due to Drugs, Jaw

Summary: patients who had bisphosphonate-related osteonecrosis of the jaw in stage ii were allocated in two groups randomly : in group1, 10 patients underwent debridement and primary closer of the area,in group 2 , patients received phenytoin + tetracycline topically in the debridement area.wound dehiscence , infection and pain were in 1,6 and 12 months after treatment.

all patients undergo surgical necrotic bone debridement in combination with antibiotic therapy (clindamycin 300 mg q8h) for 4 weeks . patients who had bron of the mandible randomly allocated in 2 groups. group 1 underwent debridement of necrotic bone and the involved area closed primary and in group 2 ,patients received topical phenytoin 5%+ tetracycline. patients were evaluated after 1(time1) ,6(time2) and 12(time 3) months. the size of bone lesion was measured by using come beam computer tomography (cbct). wound dehiscence (stage 0 :no dehiscence ,stage 1: less than 10 mm dehiscence,stage 2 : more than 10 mm dehiscence) infection: pus, sinus tract (yes/no) pain according to visual analog scale (vas) 0-10.in the third follow up time ( 12 months) ,the number of patients who were a time span of 3 months without clinical symptoms were documented in each group.

Eligibility criteria:
inclusion criteria: * criteria of bisphosphonate-related osteonecrosis in stage ii * need debridement and surgical intervention exclusion criteria: * malignancy in the area * history of chemotherapy , * diabetic mellitus * hiv * odontogenic infection or undergo dialysis

Keywords: osteonecrosis mandible
the efficacy and tolerability of 12-weeks treatment with almond and buckwheat based formula in pediatric patients with active eoe

Conditions: Eosinophilic Esophagitis

Summary: eosinophilic esophagitis (eoe) is a chronic, relapsing, immune-mediated esophageal disease. clinical manifestations in infants and toddlers generally include vomiting, food refusal, choking with meals and, less commonly, failure to thrive. the management of the disease includes dietary and pharmaceutical interventions, and the goal of the treatment should ideally be both the resolution of symptoms and the normalization of the macroscopic and microscopic abnormalities. milk is the most common food trigger identified, followed by wheat, soy, and eggs. the aim of the study is to examine the tolerability of a new plant based formula made of minimally processed almond and buckwheat and enriched with vitamins and minerals.


Eligibility criteria:
inclusion criteria: * pediatric patients with active eoe (naïve and experienced) * ages 1-18 years exclusion criteria: * change in dosing of proton pump inhibitors (ppi) medication * local steroid treatment \< 1 month * refusal to comply with study protocol * known allergy to almonds and buckwheat * use of dairy during the study
physical activity to mitigate preeclampsia risk

Conditions: Pre-Eclampsia

Summary: the purpose of this study is to compare the effects of aerobic (ae), resistance (re), and combination (aere) exercise throughout pregnancy on selected maternal and fetal/neonatal physiological variables in women at-risk for preeclampsia. the central hypothesis of this project is that exercise will decrease severity and occurrence of preeclampsia symptoms, thus improving maternal, pregnancy, and birth outcomes. aim 1. determine the influence of different exercise modes during pregnancy at risk of preeclampsia on maternal cardiometabolic health. aim 2. determine the most effective exercise mode in pregnancy at risk of preeclampsia on improving birth and infant health outcomes.

approximately 5% of pregnancies worldwide and in the united states were complicated by preeclampsia. women who develop preeclampsia in pregnancy go on to develop cardiovascular issues (catov and other studies). further, infants from preeclamptic pregnancies are at increased risk of mortality and co-morbid conditions (hypertension, excessive weight gain, increased bmi). however, preliminary data suggests that exercise will attenuate or prevent the severity and risk of preeclampsia; thus improving health for women and children. the purpose of this study is to compare the effects of aerobic (ae), resistance (re), and combination (aere) exercise throughout pregnancy on selected maternal and fetal/neonatal physiological variables in women at-risk for preeclampsia. the investigators hypothesize that following changes will occur:(1) improvements in the measurements of maternal resting heart rate, blood pressure, cardiometabolic risk (cmr) score, placental growth factor (plgf), preeclampsia severity, onset of preeclampsia of symptoms at each time point (once per visit); and (2) improvements in birth and infant measurements of decreased c-sections, preterm deliveries, hospital stay, birth weight, placental efficiency at birth when exposed to different modes of maternal exercise compared no exercise (usual care) with greatest differences in aere trained group. ultimately, our goal is to determine which exercise program is most effective at attenuating or preventing preeclampsia and thus improving health outcomes for mother and child.

Eligibility criteria:
inclusion criteria: * healthy women, age 18-40 years, \<16 weeks' gestation, with singleton pregnancy; women (bmi:18.5-45.0), sedentary, cleared by their obstetric provider. exclusion criteria: * pre-existing chronic conditions such as hiv, lupus, etc.; taking medicines that affect fetal development; and/or lack of telephone or email contact information).
does simvastatin affect insulin sensitivity in dyslipidemic type 2 diabetic patients?

Conditions: Hypercholesterolemia; Diabetes; Cardiovascular Disease

Summary: we aimed to address the issue whether statins affect insulin resistance. to this end, we combined the available state-of-the art technology for detailed assessment of both whole-body and tissue specific insulin sensitivity in vivo in humans (euglycemic-hyperinsulinemic clamp, stable isotope \[6,6-2h2\]glucose dilution technique, proton nuclear magnetic resonance spectroscopy - 1h mrs - of liver and skeletal muscle). outcome measures were determined before and after 8 weeks therapy with 80 mg simvastatin in hypercholesterolemic patients with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * type 2 diabetic patients with known duration of disease: 3-10 years * age: 35-75 years * bmi\<32 kg/m2 * hypercholesterolemia: fasting serum low density lipoprotein (ldl) * cholesterol concentration \< 4.16 mmol/l (\<160 mg/dl) * normotriglyceridemia: fasting plasma triglyceride concentration \< 2.75 mmol/l (250 mg/dl) * creatinine levels \< 1.8 mg /dl * liver transaminases \< 20% over the upper limit with no active liver disease and ck \< 50% above the upper limit * blood pressure less than 160/100 mmhg were accepted as eligible for enrollment exclusion criteria: * hypertension, cardiovascular disease or metabolic diseases other than t2dm as determined by medical history, physical examination and routine laboratory tests * alcohol consumption (more than 10 drinks/week) * poor glycemic control (hba1c\<9%) * patients requiring insulin, patients with type 1 diabetes * patients taking any medicine known to interfere with metabolism of statins or with insulin sensitivity as summarized in an exclusionary drug table * patients receiving any hypolipidemic medication or diet during the last 2 months before enrollment

Keywords: insulin resistance statins muscle and liver triglycerides
immune profile of saliva and serum of patients with primary sjögren´s syndrome

Conditions: Sjogren's Syndrome

Summary: primary sjögren's syndrome (pss) is a chronic systemic inflammatory disease, which mainly affects the lacrimal and salivary glands, leading to sicca syndrome. pss has a probable autoimmune etiology, with the production of several autoantibodies such as antinuclear antibodies (ana), anti-ro/ss-a, anti-la/ss-b, rheumatoid factor (rf) and cryoglobulins. recently, our group described a high frequency of antibodies directed to dnase i in the serum of pss patients and these antibodies were associated with the presence of the anti-epstein-barr (ebv) early antigen diffuse (anti-ea-d). this finding becomes interesting considering the recent description of reduction of dnase i activity in the tear of patients with xerophthalmia of different causes, which would result in an accumulation of extracellular dna and neutrophilic inflammatory infiltrate on the ocular surface. this hypothesis is reinforced by the observation that treatment with dnase i as eye drops results in clinical improvement of dry eye. in addition, it has been shown that periodontal disease is an aggravating factor of xerostomia in pss, as it leads to a chronic inflammatory process and, consequently, to the destruction of minor salivary glands. therefore, the objective of the present study will be to evaluate the presence of antibodies directed to dnase i in the saliva and serum of pss patients and its possible capacity of inhibition of the enzyme before and after treatment of periodontal disease. such findings will be correlated with the presence of periodontal disease, with the glandular and extraglandular manifestations of ssp and also with the presence of ebv dna in the serum and oral lavage of these patients.


Eligibility criteria:
inclusion criteria: * patients with primary sjögren's syndrome according to 2016 eular/acr classification criteria, and healthy people without any rheumatic disease/symptoms of sicca syndrome * patients regularly followed at the sjögren's syndrome outpatient clinic of rheumatology division exclusion criteria: * use of drugs that cause oral dryness (mainly antidepressants and antihistamines). * patients with history of head and neck radiation therapy. * current smoking. * pregnancy and/or lactation. * history of periodontal treatment for at least 6 months prior to enrollment.